Last reviewed · How we verify
KD025
At a glance
| Generic name | KD025 |
|---|---|
| Also known as | belumosudil, SLx-2119 |
| Sponsor | Kadmon, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD (PHASE1)
- Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease (PHASE2)
- Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (PHASE2)
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) (PHASE2)
- Immunological Tolerance in Patients With Mismatched Kidney Transplants (PHASE1)
- A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (PHASE3)
- A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects (PHASE1)
- A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KD025 CI brief — competitive landscape report
- KD025 updates RSS · CI watch RSS
- Kadmon, a Sanofi Company portfolio CI